HF
SYRE icon

HRT Financial’s Spyre Therapeutics SYRE Stock Holding History

HRT Financial’s Portfolio SYRE Stock Details SYRE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-78,996
Closed -$3M – 3073
2024
Q1 		$3M Buy
+78,996
New +$2.29M 0.02% 420
2023
Q3 		– Sell
-6,581
Closed -$74K – 3070
2023
Q2 		$74K Buy
+6,581
New +$31.2K ﹤0.01% 2003
2023
Q1 		– Sell
-1,999
Closed -$22K – 3173
2022
Q4 		$22K Buy
+1,999
New +$35.9K ﹤0.01% 2173

Other funds holding SYRE

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.38B AUM 407.79% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
B
Braidwell Stamford, Connecticut $3B AUM 46.72% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
CC
Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

HRT Financial's SYRE Position: Q2 2024 in Review

HRT Financial sold out of Spyre Therapeutics (SYRE) in Q2 2024, closing a stake of 78,996 shares — an estimated $3M sold.

HRT Financial first reported a position in SYRE in Q4 2022 and held it in 3 quarters. The position peaked at $3M in Q1 2024. 107 funds tracked by Wall St. Rank hold SYRE as of Q2 2024.

  • HRT Financial reported no remaining Spyre Therapeutics position as of Q2 2024 after selling out during the quarter.
  • HRT Financial sold 78,996 Spyre Therapeutics shares in Q2 2024, an estimated $3M.
  • HRT Financial first reported a position in Spyre Therapeutics in Q4 2022 and held it in 3 quarters.
  • HRT Financial's Spyre Therapeutics position peaked at $3M in Q1 2024.
  • 107 funds tracked by Wall St. Rank held Spyre Therapeutics as of Q2 2024.

Based on HRT Financial's 13F filing for Q2 2024, filed 12 Aug 2024.